Preview

Медицинский Совет

Расширенный поиск

ВАКЦИНАЦИЯ В РЕВМАТОЛОГИИ: ЭВОЛЮЦИЯ ВЗГЛЯДОВ НА ПРОБЛЕМУ

https://doi.org/10.21518/2079-701X-2017-5-142-147

Полный текст:

Аннотация

В современной ревматологии несомненного внимания заслуживает проблема коморбидных инфекций, формирование которых обусловлено как самим ревматическим заболеванием (РЗ), так и необходимостью применения препаратов с иммуносупрессивным действием. Многочисленные проблемы, обусловленные инфекциями в ревматологии и иных отраслях клинической медицины, нельзя решить только путем использования большого количества антиинфекционных препаратов, которые доступны на сегодняшний день. Следовательно, в ближайшей перспективе важная роль будет отведена созданию, совершенствованию  и быстрому (по возможности) внедрению в клиническую  практику вакцин различной направленности. В данном обзоре рассмотрены вопросы, касающиеся применения вакцин против гриппа и пневмококковой инфекции у больных РЗ, а также сформулированы  перспективы дальнейшего внедрения вакцинопрофилактики в ревматологии.

Об авторах

Б. С. Белов
Научно-исследовательский институт ревматологии имени В.А. Насоновой
Россия

Доктор медицинских наук.

Москва



М. С. Наумцева
Научно-исследовательский институт ревматологии имени В.А. Насоновой
Россия

Кандидат медицинских наук.

Москва



Г. М. Тарасова
Научно-исследовательский институт ревматологии имени В.А. Насоновой
Россия

Кандидат медицинских наук.

Москва



Список литературы

1. Ranjan P et al. Immunization in Patients with Rheumatic Diseases: A Practical Guide for General Practitioners. Journal of Clinical and Diagnostic Research, 2015, 9(5): OE01-OE04.

2. Bernatsky S, Hudson M, Suissa S. Antirheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford), 2007, 46(7): 1157-1160.

3. Franklin J et al. Risk and predictors of infection leading to hospitalisation in a large primarycare-derived cohort of patients with inflammatory polyarthritis. Annals of the rheumatic diseases, 2007, 66(3): 308-312.

4. Kroesen S et al. Serious bacterial infections in patients with rheumatoid arthritis under antiTNF-alpha therapy. Rheumatology, 2003, 42(5): 617-621.

5. Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. Journal of epidemiology and community health, 2012, 66(12): 1177-1181.

6. Костинов М.П., Тарасова А.А. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваниях. М.: МДB, 2009. 252 с.

7. Bernatsky S, Hudson M, Suissa S. Antirheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford), 2007, 46(7): 1157-1160.

8. Coyne P et al. Acute lower respiratory tract infections in patients with rheumatoid arthritis. The Journal of rheumatology, 2007, 34(9): 1832-1836.

9. Lanternier F et al. Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Annals of the rheumatic diseases, 2008, 67(7): 1047.

10. Pradeep J, Watts R, Clunie G. Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Annals of the rheumatic diseases, 2007, 66(6): 837-838.

11. Dougados M et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, crosssectional study (COMORA). Annals of the rheumatic diseases, 2014, 73(1): 62-68.

12. Atzeni F et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmunity reviews, 2012, 12(2): 225-229.

13. Kuroda Y et al. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomedicine & pharmacotherapy, 2004, 58(5): 325-337.

14. Bach JF. Protective role of infections and vaccinations on autoimmune diseases. Journal of autoimmunity, 2001, 16(3): 347-353.

15. Brodman R et al. Influenzal vaccine response in systemic lupus erythematosus. Annals of internal medicine, 1978, 88(6): 735-740.

16. Herron A et al. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. Journal of the American Medical Association, 1979, 242(1): 53-56.

17. Croft SM et al. Specific antibody response after in vivo antigenic stimulation in systemic lupus erythematosu. The Journal of rheumatology, 1984, 11(2): 141-146.

18. Battafarano DF et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis and rheumatism, 1998, 41(10): 828-834.

19. Mercado U. Why have rheumatologists been reluctant to vaccinate patients with systemic lupus erythematosus? The Journal of rheumatology, 2006, 33(8): 1469-1471.

20. Kaine JL et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. The Journal of rheumatology, 2007, 34(2): 272-279.

21. Kapetanovic MC et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford), 2006, 45(1): 106-111.

22. Mori S et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Annals of the rheumatic diseases, 2013, 72(8): 1362-1366.

23. Bingham CO 3rd et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Annals of the rheumatic diseases, 2015, 74(5): 818-822.

24. Burmester GR et al. Tofacitinib, an oral Janus kinase inhibitor: safety comparisonin patients with rheumatoid arthritis and an inadequate response to nonbiologic or biologic diseasemodifying anti-rheumatic drugs. Arthritis and rheumatism, 2013, 65(10 Suppl): 192.

25. Hua C et al. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis care and research, 2014, 66(7): 1016-1026.

26. Kapetanovic MC et al. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis research and therapy, 2013, 15(5): R171.

27. Schiff M et al. Response to pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the arrive trial. Annals of the rheumatic diseases, 2007, 66(Suppl. II): 437.

28. Pham T et al. Abatacept therapy and safety management. Joint, bone, spine: revue du rhumatisme, 2009, 76(Suppl. 1): 3-84.

29. Winthrop KL et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Annals of the rheumatic diseases. http://ard.bmj.com/content/early/2015/03/20/annrheumdis-2014-207191.full.

30. Kapetanovic MC et al. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis research and therapy, 2013, 15(1): R1.

31. Plotkin SA. Correlates of protection induced by vaccination. Clinical and vaccine immunology, 2010, 17(7): 1055-1065.

32. Kavanaugh A. Infection prophylaxis in antirheumatic therapy: emphasis on vaccination. Current opinion in rheumatology, 2009, 21(4): 419-424.

33. Brezinschek HP et al. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Current opinion in rheumatology, 2008, 20(3): 295-299.

34. Bengtsson C et al. Commonvaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Annals of the rheumatic diseases, 2010, 69(10): 1831-1833.

35. Наумцева М.С. Оценка иммуногенности и безопасности 23-валентной полисахаридной пневмококковой вакцины у больных ревматоидным артритом. Автореферат дис. ... канд. мед. Москва, 2016, 22 стр.

36. Bijl M et al. Vaccination of patients with autoimmune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmunity reviews, 2012, 11(8): 572-576.

37. Ferreira I, Isenberg D. Vaccines and biologics. Annals of the rheumatic diseases, 2014, 73(8): 1446-1454.

38. Perry LM. Winthrop KL, Curtis JR. Vaccinations for rheumatoid arthritis. Current rheumatology reports, 2014, 16(8): 431.


Для цитирования:


Белов Б.С., Наумцева М.С., Тарасова Г.М. ВАКЦИНАЦИЯ В РЕВМАТОЛОГИИ: ЭВОЛЮЦИЯ ВЗГЛЯДОВ НА ПРОБЛЕМУ. Медицинский Совет. 2017;(5):142-147. https://doi.org/10.21518/2079-701X-2017-5-142-147

For citation:


Belov B.S., Naumtseva M.S., Tarasova G.M. VACCINATION IN RHEUMATOLOGY: EVOLUTION OF VIEWS ON THE PROBLEM. Medical Council. 2017;(5):142-147. (In Russ.) https://doi.org/10.21518/2079-701X-2017-5-142-147

Просмотров: 1470


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)